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INTRODUCTION
Transitional cell carcinoma (TCC) of the upper urinary
tract (UUT), including ureteral and renal pelvic TCC, is rel-
atively uncommon. Renal pelvic TCC accounts for 5% of all
urothelial tumors, 10% of all renal tumors, and is 3 to 4 times
more common than ureteral TCC (1-3). Nephroureterecto-
my with bladder cuff excision is the standard treatment for
UUT-TCC. In general, UUT-TCC shows high local or sys-
temic failure, even after radical surgery (4, 5). T stage, tumor
grade, and lymphovascular invasion have been suggested as
prognostic factors of UUT-TCC. Of these factors, T stage is
the most closely associated risk factor (4-9). 
The renal pelvis is surrounded by renal parenchyma and
perirenal fat posterolaterally, but is covered with peripelvic
fat anteromedially. Despite this structural complexity, all
renal pelvic tumors that invade beyond muscularis into
peripelvic fat or renal parenchyma are diagnosed as stage
pT3 according to the TNM system by the American Joint
Committee on Cancer (AJCC) (10). Some urologists and
pathologists have been interested in this problematic issue,
but few authors have completed studies on substaging pT3
renal pelvic TCC because of their rarity (11, 12).
To elucidate the prognostic impact of peripelvic fat inva-
sion in pT3 renal pelvic TCC, we retrospectively reviewed
our single center experience with patients who had been
treated for renal pelvic TCC by open surgery. 
MATERIALS AND METHODS
The study population
We retrospectively reviewed patients who had been treated
surgically for renal pelvic TCC at our institution between
1986 and 2004. Exclusion criteria included the presence of
a distant metastasis at diagnosis, unresectable disease, and
concomitant invasive bladder cancer. Patients who had con-
comitant ureteral cancer with a higher T stage than the renal
pelvic lesion were also excluded. A study population of 128
consecutive patients was identified with 99 male patients
(77.3%) and 29 female patients (22.7%). The median age
was 63 yr (30-81) and the median follow-up duration was
56 months (range, 6 to 240).
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Prognostic Impact of Peripelvic Fat Invasion in pT3 Renal Pelvic
Transitional Cell Carcinoma
Renal pelvic transitional cell carcinoma (TCC), which invades beyond muscularis
into peripelvic fat or the renal parenchyma, is diagnosed as stage pT3 despite its
structural complexity. We evaluated the prognostic impact of peripelvic fat invasion
in pT3 renal pelvic TCC. Between 1986 and 2004, the medical records on 128
patients who were surgically treated for renal pelvic TCC were retrospectively review-
ed. Sixty patients with pT3 disease were eligible for the main analysis. The prog-
nostic impact of various clinicopathological factors was analyzed using univariate
and multivariate analyses. On univariate analysis, sex, age, concomitant bladder
tumors, concomitant ureter tumors, lymphadenectomy, adjuvant chemotherapy,
tumor grade, multiplicity, renal parenchymal invasion, and carcinoma in situ did not
influence the disease-specific survival (p>0.05). By contrast, peripelvic fat inva-
sion, lymph node invasion, and lymphovascular invasion were each significantly
associated with disease-specific survival (p<0.05). Multivariate analysis showed
that peripelvic fat invasion (p=0.012) and lymph node invasion (p=0.004) were
independent prognostic factors. In conclusion, peripelvic fat invasion is a strong
prognostic factor in pT3 renal pelvic TCC. Thus, systemic adjuvant therapy should
be considered in the presence of peripelvic fat invasion, even if the lymph nodes
are not involved.
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Treatments and follow-ups
All patients had undergone radical nephroureterectomy,
and lymphadenectomy was performed on selected patients
when enlarged lymph nodes were encountered intraopera-
tively or noted on preoperative computed tomography. In
this procedure, the hilar and regional nodes adjacent to the
ipsilateral great vessel were resected. As postsurgical adju-
vant therapy, cisplatin-based chemotherapy was administer-
ed to 22 patients. Patient follow-up was relatively uniform
including surveillance cystoscopy, urine cytology, abdomen-
pelvis computed tomography, and a chest radiography. These
tests were performed at 3-month intervals for the initial 2
yr, every 6-months for the subsequent 3 yr, and annually after
the initial 5 yr. In addition, whole-body bone scan was check-
ed annually during follow-up. 
Study methods
Clinical information was obtained by a retrospective review
of medical records in all patients. Survival information was
obtained from medical records and our cancer center database.
At the last follow-up, 80 patients (62.5%) were alive, 39
patients (30.5%) had died of cancer, and 9 (7.0%) had died
of other causes. Pathology slides were reassessed by one uro-
logic pathologist (NHC). Nineteen tumors (14.9%) were
stage Ta, 25 tumors (19.5%) were T1, 14 tumors (10.9%)
were T2, 60 tumors (46.9%) were T3, and 10 tumors (7.8%)
were T4, based on the 2002 American Joint Committee on
Cancer (AJCC) TNM staging system (10). Ninety-three
tumors (72.6%) were high-grade, and 35 tumors were low-
grade (27.4%) according to the 1998 World Health Organi-
zation/International Society of Urologic Pathologists (WHO/
ISUP) classification of papillary urothelial neoplasm (13).
Therefore, 60 patients with pT3 disease were eligible for
the analyses. The clinical and pathological characteristics of
these patients are specified on Table 1. 
We investigated the impact of various clinicopathological
factors on disease-specific survival. We assessed the following
prognostic factors: sex, age, concomitant bladder tumors, con-
comitant ureter tumors, lymphadenectomy, adjuvant chemo-
therapy, tumor grade, multiplicity, parenchymal invasion,
peripelvic fat invasion, lymph node invasion, carcinoma in
situ, and lymphovascular invasion. Kaplan-Meier curves were
generated and compared using the log-rank test for the uni-
variate survival analyses. To assess the independent impact
of clinicopathological factors on the disease-free survival,
Cox proportional hazards regression was used for the multi-
variate survival analyses. The final result for the multivari-
ate models was obtained using a stepwise forward selection
strategy. SPSS for Windows version 12.0 was used for statis-
tical analyses, and a two-sided p value of less than 0.05 was
considered to be significant.
RESULTS
Of the 60 patients with pT3 renal pelvic TCC, 30 patients
(50.0%) were alive at the final follow-up, and 4 patients (6.7
%) had died of other causes. Twenty-six patients (43.3%)
had died of renal pelvic TCC, and the median time to can-
cer-related death was 28 months (6-102 months). The 5-yr
disease-specific survival rate was 59.0%, and the 10-yr dis-
ease-specific survival rate was 38.8%. 
No. of patients %
Sex 
Male 48 80.0
Female 12 20.0
Age
< 65 yr 28 46.7
≥65 yr 32 53.3
Laterality
Right 21 35.0
Left 39 65.0
Concomitant bladder tumor
Yes 9 15.0
No 51 85.0
Concomitant ureter tumor
Yes 8 13.3
No 52 86.7
Lymphadenectomy
Yes 30 50.0
No 30 50.0
Adjuvant chemotherapy
Yes 15 25.0
No 45 75.0
Tumor grade
Low 8 13.3
High 52 86.7
Multiplicity
Yes 12 20.0
No 48 80.0
Parenchymal invasion
Yes 50 83.3
No 10 16.7
Peripelvic fat invasion
Yes 19 31.7
No 41 68.3
Lymph node invasion
pN0 or pNx 51 85.0
pN+ 9 15.0
Carcinoma in situ
Yes 4 6.7
No 56 93.3
Lymphovascular invasion
Yes 17 28.3
No 43 71.7
Total 60 100.0
Table 1. Clinical and pathological characteristics of the patients
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According to the univariate analysis, sex, age, concomitant
bladder tumors, concomitant ureter tumors, lymphadenec-
tomy, adjuvant chemotherapy, tumor grade, multiplicity,
parenchymal invasion and carcinoma in situ did not influ-
ence disease-specific survival. On the other hand, peripelvic
fat invasion (p=0.038), lymph node invasion (p<0.001), and
lymphovascular invasion (p=0.017) were each significantly
associated with disease-specific survival (Fig. 1) (Table 2).
Statistically proven prognostic factors including peripelvic
fat invasion, lymph node invasion, and lymphovascular inva-
sion were subjected to multivariate Cox proportional haz-
ards regression analysis to assess the independent impact of
these factors. Using this multivariate analysis, significant
differences in disease-specific survival rates were found in
patients with peripelvic fat invasion (p=0.012) and lymph
node invasion (p=0.004). The hazard ratios of disease-specif-
ic survival were 2.90 for cases with peripelvic fat invasion
and 3.70 in cases with lymph node invasion. However, cases
with lymphovascular invasion did not show a significant dif-
ference through multivariate analysis (Table 3).
Based on these results, we subdivided the conventional
pT3 stage patients into those with peripelvic fat invasion
D
i
s
e
a
s
e
-
s
p
e
c
i
f
i
c
 
s
u
r
v
i
v
a
l
1.0
0.8
0.6
0.4
0.2
0.0
0 50 100 150 200 250
Follow-up duration (months)
Peripelvic fat invasion (+)
p<0.001, Ta, 1 vs. T2
p=0.453, T2 vs. T3a
p=0.038, T3a vs. T3b
p=0.043, T3b vs. T4
p=0.038
Peripelvic fat invasion (-)
Fig. 1. Disease-specific survival probabilities in patients with pT3
renal pelvic cancer according to peripelvic fat invasion (A), and
in patients with all renal pelvic cancer when separated accord-
ing to the T stages (B).
T3a, T3 tumors without peripelvic fat invasion; T3b, T3 tumors with
peripelvic fat invasion.
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Ta, 1
T2
T3a
T3b
T4
5-yr disease-specific
survival (%)
p value
Sex 0.314
Male 61.0
Female 54.5
Age 0.755
<65 yr 70.1
≥65 yr 47.7
Concomitant bladder tumor 0.712
Yes 64.8
No 57.7
Concomitant ureter tumor 0.521
Yes 87.5
No 54.2
Lymphadenectomy 0.271
Yes 53.9
No 64.0
Adjuvant chemotherapy 0.917
Yes 51.4
No 60.2
Tumor grade 0.167
Low 66.6
High 56.1
Multiplicity 0.353
Yes 83.3
No 52.7
Parenchymal invasion 0.652
Yes 56.2
No 75.0
Peripelvic fat invasion 0.038
Yes 48.0
No 63.9
Lymph node invasion <0.001
pN0 or pNx 68.9
pN+ 11.1
Carcinoma in situ 0.486
Yes 33.3
No 60.8
Lymphovascular invasion 0.011
Yes 26.2
No 69.8
Table 2. Univariate analysis for the disease-specific survival
rates
Prognostic factors Hazard ratio p value 95% Confi-
dence interval
Lymph node invasion 3.70 1.504-9.113 0.004
Lymphovascular invasion 2.23 0.937-5.308 0.070
Peripelvic fat invasion 2.90 1.268-6.634 0.012
Table 3. Multivariate analysis for the disease-specific survival
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and those without. The prognosis of those with peripelvic
fat invasion was more similar to that of pT4 tumors than
conventional pT3 tumors, but a statistical difference still
existed between them (p=0.043). The prognosis of those
without peripelvic fat invasion was similar to that of pT2
disease, and we could not find any difference in the progno-
sis of patients with pT2 tumors and pT3 disease without
peripelvic fat invasion (p=0.453) (Fig. 1).
DISCUSSION
The current staging system of UUT-TCC has been chal-
lenged for many reasons. The pathologic findings, patho-
genesis, clinical manifestation, and natural history of renal
pelvic and ureteral TCC are similar, and thus they have been
considered identical diseases. However, questions remain as
to whether renal pelvic and ureteral TCC are similar in terms
of prognosis because of their apparent anatomical differences.
Moreover, several studies have shown that ureteral TCC is
associated with a higher local or distant failure rate than renal
pelvic TCC and that ureteral TCC is associated with a poor-
er prognosis (7, 14, 15). The ureter is surrounded by an exten-
sive plexus of ureteral blood vessels and lymphatics, while
on the other hand, the renal pelvis is more firmly covered
by adjacent tissue, such as the kidney and perihilar adipose
tissue. Park et al. suggested that this anatomical weakness
of the ureter was responsible for their study results (7). 
Another problematic issue has been raised regarding renal
pelvic TCC. The staging of renal pelvic TCC has frequently
been discussed in the literature (11, 12, 16, 17). In 1971,
Grabstald et al. classified 70 cases of renal pelvic tumors into
4 staging groups based on a previous staging of transitional
cell carcinoma of the bladder (16, 18). In this study, group
IV tumors were defined as those with peripelvic or perirenal
fat extensions and adjacent structural invasion. In other words,
those patients with peripelvic fat invasion (group IV) were
regarded as having higher stage tumors than those with renal
parenchymal invasion (group III) (16). Rubenstein et al. modi-
fied the Grabstald classification and also separated tumors
with peripelvic fat invasion (stage C) from tumors with renal
parenchymal extension (stage B) (17). Unfortunately, these
series of studies on renal pelvic cancers were small, and alth-
ough survival percentages for each stage were given, the dif-
ferences between these stages could not be analyzed statisti-
cally. Nonetheless, the AJCC TNM system for UUT-TCC
was formulated to standardize staging in 1988, but renal
pelvic TCC with renal parenchymal or peripelvic fat inva-
sion were both considered to be identical pT3 stages of renal
pelvic TCC (19). 
Two previous reports have statistically evaluated the prog-
nostic impact of peripelvic fat invasion. Yoshimura et al.
demonstrated that the 3-yr cause-specific survival rates were
55.6% in patients with pT3 renal pelvic tumors containing
peripelvic fat invasion and 64.9% in patients without this
invasion (12). However, no statistical difference was found
between the two groups. A study by Olgac et al. also report-
ed that cases with hilar fat invasion and renal parenchymal
invasion had similar outcomes (11). By contrast, in our study,
the disease-specific survival rate of pT3 renal pelvic TCC
showed a significant difference according to peripelvic fat
invasion and lymph node invasion. The prognosis of pT3
tumors with peripelvic fat invasion was more similar to that
of pT4 tumors than conventional pT3 tumors. Because of
this adjustment, the survival curve of those without peripelvic
fat invasion was more similar to pT2 disease. In other words,
disease risk has been overestimated in a subset of pT3 renal
pelvic TCC patients. 
Our results could be explained by a number of mecha-
nisms. The anteriomedial portion of the renal pelvis is sur-
rounded by an extensive plexus of ureteral blood vessels and
lymphatics similar to the ureter. This led to the hypothesis
that it is easier for those with peripelvic fat invasion than
those without to invade lymph vessels. Another explanation
may be a problem related to surgical techniques. Because
some extent of hilar dissection is required for vascular con-
trol, a part of the peripelvic fat layer might be destroyed dur-
ing this procedure. For this reason, a more meticulous hilar
dissection should be required in renal pelvic TCC, especial-
ly in the tumors that are located in the anteriomedial part of
the renal pelvis. Although adjuvant cisplatin-based chemother-
apy did not improve oncological outcomes in the pT3 patients
of our study (Table 2), more aggressive adjuvant chemother-
apy should be considered for those with peripelvic fat inva-
sion. Outcomes of this strategy, such as whether adjuvant
chemotherapy has survival benefits for these patients, should
be evaluated based on a larger study population.
There are some limitations in our current study. To clarify
risk factors in pT3 patients, we excluded tumors of other
stages (pTa, pT1, pT2 and pT4) for the main analysis. In
addition to their rarity, this exclusion criterion also caused a
relatively small study population. Another limitation is that
we did not perform routine lymphadenectomies. Of the 60
patients with pT3 renal pelvic cancers, the rate of lymph
node positive pT3 tumors was 15%, though there is a pos-
sibility that this rate may be underestimated. Meanwhile,
we classified patients with pN0 or pNx as the same entity
during our univariate analysis because we could not identify
any prognostic differences between them (data not shown).
However, this factor might play a role as a confounding fac-
tor. Thus, a more refined study population through routine
lymphadenectomy would be helpful for controlling these
confounding variables, and a larger number of cases would
be required to elucidate these observations.
In conclusion, peripelvic fat invasion is a strong prognostic
factor in pT3 renal pelvic TCC. More meticulous hilar dissec-
tions would be helpful in the surgical treatment of renal pelvic
TCC, especially for the tumors located in the anteriomedial438 K.S. Cho, N.H. Cho, S.Y. Park, et al.
region of the renal pelvis. In addition, aggressive systemic
chemotherapy should be considered in the presence of peri-
pelvic fat invasion, even if the lymph nodes are not involved.
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